Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia: Pathological Mechanism and Treatment Progress---Review.
10.19746/j.cnki.issn.1009-2137.2021.05.049
- Author:
Meng-Zhen HUANG
1
,
2
,
3
;
Shi-Xuan WANG
4
;
Fei LI
1
,
2
,
5
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanchang University
2. Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province
3. Institute of Lymphatic Tumor Diseases of Nanchang University, Nanchang 330006, Jiangxi Province, China.
4. Department of Hematology, The First Affiliated Hospital of Nanchang University,Nanchang 330006, Jiangxi Province, China.
5. Institute of Lymphatic Tumor Diseases of Nanchang University, Nanchang 330006, Jiangxi Province, China E-mail: yx021021@sina.com.
- Publication Type:Review
- MeSH:
Antibodies, Monoclonal;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell/complications*;
MicroRNAs;
Purpura, Thrombocytopenic, Idiopathic;
Thrombocytopenia
- From:
Journal of Experimental Hematology
2021;29(5):1671-1675
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) patients usually show immune dysfunction, which often leads to autoimmune hemocytopenia. Immune thrombocytopenia (ITP) is one of the common complications. The pathogenesis of CLL-related ITP is complex and has not been fully elucidated. At present, the researches mainly focus on humoral immunity, cellular immunity and innate immune disorders. Recent studies suggest that genomic abnormalities and microRNAs are also involved in CLL-related ITP. Traditional ITP standard therapy has a poor effect on CLL-related ITP. Chemotherapy or monoclonal antibody therapy against the primary pathogenesis of CLL can effectively treat thrombocytopenia, and the emergence of new targeted drugs also provides new treatment options for the disease. In this paper, the progresses of CLL-related ITP pathogenesis, prognosis and treatment in recent years are reviewed.
